TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06792201

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SARC-F, Handgrip test, Chair stand test
Description: The SARC-F questionnaire is a simple to use questionnaire consisting of five questions about daily actions.To test the force will be used: Hand-grip test and Chair stand test. The tool used for the hand-grip test is the GRIP-A (Takei). The test is performed on the dominant limb and repeated three times. The position taken by the patient will be: sitting with shoulders and elbows flexed, forearms in neutral position. The Chair stand test measures the time it takes for a patient to get up five times from a sitting position without the help of her upper limbs. The test will be timed.The measurement of lean mass will be carried out by means of a bio impedance meter. This instrument does not measure muscle mass directly but estimates it based on the electrical conductivity of the whole body. Bioimpedance is a method that is easy and safe for the patient to use.
Study: NCT06792604

Intervention type: DEVICE
Group type: OTHER
Intervention: Anal self-sampling (smear)
Description: Anal self-sampling (smear) at M12, M24 and M36 (each year) for HPV16+ patients at M0 and anal self-sampling (smear) at M36 for HPV16- at M0
Study: NCT06792604

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HPV questionnaire
Description: HPV questionnaire at each visit M0, M12, M24 and M36 for HPV16-positive patients at M0 and HPV questionnaire at each visit M0, 4 and M36 for HPV16-negative patients
Study: NCT04782258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan Suspension
Description: Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan Tablets
Description: Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets.
Study: NCT06636500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG001419
Description: Oral doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral doses
Study: NCT06790953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group- A Conventional Sensed Mouth Wash
Description: In Group- A Conventional Sensed Mouth Wash will be used for treatment of Dentin hypersensitivity.~Visual Analogue scoring system will be used to calculate the dentin hypersensitivity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group-B Novel Titania nanoparticles enriched Mouth Wash
Description: In Group-B Novel Titania nanoparticles enriched Mouth wash will be used to treat the Dentin hypersensitivity.~Visual Analogue scoring system will be used to calculate the dentin hypersensitivity.
Study: NCT06790706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOMVANALIMAB + ZIMBERELIMAB
Description: Patients will be treated with intravenous Domvanalimab at flat dose of 1200 mg + intravenous Zimberelimab at flat dose of 360 mg, administered every 3 weeks (Q3W, one cycle = 3 weeks).
Study: NCT04720339

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Molecular monitoring by quantification of cell-free DNA
Description: Molecular monitoring by quantification of cell-free DNA (absolute value and variation from baseline) of two house-keeping genes (RPP30, TMEM11) by droplet digital PCR, during based-immunotherapy treatments of NSCLC patients.~Cell-free DNA will be extracted from 4 ml of plasma before treatments by immunotherapy, obtained from blood Streck® tubes.~Quantification of house-keeping genes (or mutated genes if some are previously routinely identified in tumor tissue) by ddPCR.
Study: NCT05480241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancreatic Enzyme Replacement Therapy
Description: Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + Omeprazole 20mg once daily on fasting
Study: NCT05704842

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Home-based exercise program including core exercises as follows: Core Stabilization, core extension, leg extensions, squats with and without weights, shoulder and arm exercises.
Study: NCT04504019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: USCTR
Description: Ultrasound guided CTR via a single \< 1 cm wrist or palmar incision. The procedure will be performed using the SX-One MicroKnife®, also known as UltraGuideCTR

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mOCTR
Description: Mini-open CTR via a single 1-3cm palmar incision
Study: NCT04971369

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-NY001
Description: 89Zr-NY001 injection followed by 89Zr-NY001 PET scan
Study: NCT06790706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOMVANALIMAB + ZIMBERELIMAB
Description: Patients will be treated with intravenous Domvanalimab at flat dose of 1200 mg + intravenous Zimberelimab at flat dose of 360 mg, administered every 3 weeks (Q3W, one cycle = 3 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOMVANALIMAB + ZIMBERELIMAB
Description: Patients will be treated with intravenous Domvanalimab at flat dose of 1200 mg + intravenous Zimberelimab at flat dose of 360 mg, administered every 3 weeks (Q3W, one cycle = 3 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOMVANALIMAB + ZIMBERELIMAB
Description: Patients will be treated with intravenous Domvanalimab at flat dose of 1200 mg + intravenous Zimberelimab at flat dose of 360 mg, administered every 3 weeks (Q3W, one cycle = 3 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4
Description: Patients will be treated with intravenous Domvanalimab at flat doses of 1600 mg + intravenous Zimberelimab at flat dose of 480 mg, administered every 4 weeks (Q4W), together with an induction treatment of intravenous FOLFOX-4 (Oxaliplatin 85 mg/m2 IV, L-folinic acid 200 mg/m2 IV, and fluorouracil 400 mg/m2 IV bolus on Day 1, fluorouracil 2400 mg/m2 IV continuous infusion over 46-48 hours starting on Day 1) given every 2 weeks, for 4 months (one cycle = 4 weeks).
Study: NCT06472453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allograft/Xenograft
Description: Alveolar ridge preservation of a single extraction socket site with a mixture of demineralized cortical bone substitute vallos® and xenograft Bio-Oss®.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allograft
Description: Alveolar ridge preservation of a single extraction socket site with vallos® (mineralized cortico-cancellous bone substitute)
Study: NCT05419947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERDYE powder for solution for injection 25 mg
Description: Verdye 25 mg contains sodium VI powder for solution for injection. VI is a water-soluble agent with a spectral absorption peak of 800 nm. It is a drug approved for diagnostic use only and is indicated for the measurement of the excretory function of the liver.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERDYE powder for solution for injection 25 mg
Description: Verdye 25 mg contains sodium VI powder for solution for injection. VI is a water-soluble agent with a spectral absorption peak of 800 nm. It is a drug approved for diagnostic use only and is indicated for the measurement of the excretory function of the liver.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERDYE powder for solution for injection 25 mg
Description: Verdye 25 mg contains sodium VI powder for solution for injection. VI is a water-soluble agent with a spectral absorption peak of 800 nm. It is a drug approved for diagnostic use only and is indicated for the measurement of the excretory function of the liver.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERDYE powder for solution for injection 25 mg
Description: Verdye 25 mg contains sodium VI powder for solution for injection. VI is a water-soluble agent with a spectral absorption peak of 800 nm. It is a drug approved for diagnostic use only and is indicated for the measurement of the excretory function of the liver.
Study: NCT06149754

Intervention type: DEVICE
Intervention: BraiN20(R) monitoring of N20 somatosensory evoked potential
Description: N20 monitoring will be carried out using the BraiN20 medical device and appropriate electrodes. The device measures one N20 wave per 33 seconds. Scalp electrodes will be located on band and wrist electrodes on a globe. The device provides an automatic reading of N20 and outcome prediction and do not require a specific training.
Study: NCT05610969

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: patients in this group will receive self-selected music after the golden moment has been completed between the patient, provider, and nursing staff

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
Study: NCT05719077

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EDITH-HC
Description: This study tests feasibility and acceptability of implementing a tool and training in a clinical practice and the preliminary efficacy of training materials to enhance hospice clinicians' knowledge of dementia-related caregiving issues at end of life and a tool for clinicians to use to address caregiving issues related to dementia at end of life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EDITH-HC
Description: This study tests feasibility and acceptability of implementing a tool and training in a clinical practice and the preliminary efficacy of training materials to enhance hospice clinicians' knowledge of dementia-related caregiving issues at end of life and a tool for clinicians to use to address caregiving issues related to dementia at end of life.
Study: NCT06423170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus GEMOX
Description: 1. Camrelizumab：200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~2. GEMOX chemotherapy : oxaliplatin 100mg/m2，D1, gemcitabine1000mg/m2，D1，intravenous infusion.~3. Carrilizumab and GEMOX chemotherapy will be intravenous infused atone day. Three weeks is a course of treatment,a total of 6-8 courses.
Study: NCT06274268

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sarcopenia diagnostic test
Description: the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.
Study: NCT04965116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progestin Only Contraceptive Pills
Description: Daily pill (placebo or active tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progestin Only Contraceptive Pills
Description: Daily pill (placebo or active tablet)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Progestin Only Contraceptive Pills
Description: Daily pill (placebo or active tablet)
Study: NCT06386536

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intelligent stationary bike
Description: A stationary motorized bike prototype that can evaluate lower limb functions such as strength, coordination, range of motion, and tonus. Based on the evaluation results, the iBike proposes a training program that is specific to each individual needs. Moreover, the intelligent bike offers diverse pedaling modes such as forward and backward pedaling, assisted pedaling, isotonic pedaling and pedaling with sensory stimulations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent stationary bike
Description: A stationary motorized bike prototype that can evaluate lower limb functions such as strength, coordination, range of motion, and tonus. Based on the evaluation results, the iBike proposes a training program that is specific to each individual needs. Moreover, the intelligent bike offers diverse pedaling modes such as forward and backward pedaling, assisted pedaling, isotonic pedaling and pedaling with sensory stimulations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional stationary bilke
Description: A conventional stationary bike that can be found in gyms or rehab centers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional stationary bilke
Description: A conventional stationary bike that can be found in gyms or rehab centers.
Study: NCT04571476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrathin bronchoscope
Description: Ultrathin bronchoscope (UTB) with an outer diameter no more than 3.0-mm and a 1.7-mm working channel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thin bronchoscope
Description: Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thin bronchoscope
Description: Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual bronchoscopic navigation combined with endobronchial ultrasound
Description: VBN can create a path to the target lesion automatically when the lesion is depicted in this software.VBN combined with EBUS can improve the diagnostic yield of PPL and shorten the examination time, which has become the standard method for the diagnosis of PPL.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual bronchoscopic navigation combined with endobronchial ultrasound
Description: VBN can create a path to the target lesion automatically when the lesion is depicted in this software.VBN combined with EBUS can improve the diagnostic yield of PPL and shorten the examination time, which has become the standard method for the diagnosis of PPL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual bronchoscopic navigation combined with endobronchial ultrasound
Description: VBN can create a path to the target lesion automatically when the lesion is depicted in this software.VBN combined with EBUS can improve the diagnostic yield of PPL and shorten the examination time, which has become the standard method for the diagnosis of PPL.
Study: NCT06384651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraosseous Vancomycin Injection
Description: * IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* IO Injection will take place into the medial malleolus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Vancomycin
Description: • Patients will receive the orthopedic surgeon's standard of care pre-operative antibiotic regimen for TAA patients. This includes IV antibiotics (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL normal saline (NS))
Study: NCT04571476

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guide sheath
Description: GS is a cannula with the thinnest outer diameter of 1.95 mm.
Study: NCT06233214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vein imaging device
Description: During the PIC application attempt, the parents of the children in the experimental group will be ensured to be with their children throughout the procedure.~PIC placement attempt will be performed on the experimental group with the help of a vein imaging device.
Study: NCT05191849

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample collection
Description: Baseline blood samples are collected before chemotherapy. Dynamic blood samples are also prospectively collected after 2\~4 cycles of chemotherapy, or at the time of disease progression.
Study: NCT05531292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model C0002
Description: Eligible subjects will be randomized in a 1:1 ratio to the investigational IOL Model C0002 in both eyes for the duration of the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Model ZCB00/DCB00
Description: Eligible subjects will be randomized in a 1:1 ratio to the control IOL Model ZCB00 in both eyes for the duration of the study.
Study: NCT05900050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-01 on top of SOC
Description: Patients will receive VS-01 intraperitoneally on four consecutive days on top of SOC

Intervention type: OTHER
Group type: OTHER
Intervention: SOC (Control Group)
Description: Patients will receive SOC for decompensated cirrhosis and ACLF
Study: NCT04496960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: XELJANZ(R) is the citrate salt of tofacitinib. Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo \[2,3-d\]pyrimidin-4-ylamino) -beta-oxo-1-piperidinepropanenitrile, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) It is freely soluble in water and has a molecular weight of 504.5 Daltons. XELJANZ(R) is supplied for oral administration as 5 mg tofacitinib (equivalent to 8 mg tofacitinib citrate) white round, immediate-release film-coated tablet. Each tablet of XELJANZ(R) contains the appropriate amount of XELJANZ(R) as a citrate salt and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, HPMC 2910/Hypromellose 6cP, titanium dioxide, macrogol/PEG3350, and triacetin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: white, round, film-coated tablet
Study: NCT05046613

Intervention type: OTHER
Intervention: Rimegepant
Description: 75mg

Intervention type: OTHER
Intervention: Not taking Rimegepant
Description: No rimegepant
Study: NCT05777031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum (CCH)
Description: Injection of intralesional CCH (0.58mg) to the penile plaque at the point of maximal curvature. Second injection of each cycle will be injected 2-3mm apart from the prior injection.
Study: NCT06527586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft contact lens
Description: Vision Correction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: soft contact lens
Description: Vision Correction
Study: NCT04916236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-4630
Description: * SHP2-inhibitor~* Powder in capsule~* Administered on day 1 and day 2 of every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-4630
Description: * SHP2-inhibitor~* Powder in capsule~* Administered on day 1 and day 2 of every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: * ERK inhibitor~* Powder in capsule~* Administered every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: * ERK inhibitor~* Powder in capsule~* Administered every day
Study: NCT05929066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC
Study: NCT05446805

Intervention type: DRUG
Intervention: F 18 AV-1451 (Flortaucipir)
Description: A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).

Intervention type: DRUG
Intervention: F 18 AV-1451 (Flortaucipir)
Description: A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).

Intervention type: DRUG
Intervention: [11C]-Pittsburgh Compound B ([11C]PiB)
Description: A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.

Intervention type: DRUG
Intervention: [11C]-Pittsburgh Compound B ([11C]PiB)
Description: A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
Study: NCT06332235

Intervention type: DRUG
Intervention: Silodosin 8 mg
Description: Dosing schedule: Oral, once daily
Study: NCT05201703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fycompa
Description: Fycompa 4 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fycompa with a boost
Description: Fycompa 4 mg daily with a boost to 6 mg daily a week before the start of your menstruation cycle until Day 4 of your cycle.
Study: NCT05929066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT04547439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin 3 mg will be taken nightly for 8 weeks
Study: NCT05019352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb cytokine adsorber
Description: device for extracorporeal hemoadsorption

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRRT
Description: continuous renal replacement therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRRT
Description: continuous renal replacement therapy